Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum

Authors

  • Fred Saad
  • Christina Canil
  • Antonio Finelli
  • Sebastien J. Hotte
  • Shawn Malone
  • Bobby Shayegan
  • Alan I. So
  • Lorne Aaron
  • Naveen S. Basappa
  • Henry J. Conter
  • Brita Danielson
  • Geoffrey Gotto
  • Robert J. Hamilton
  • Jason P. Izard
  • Anil Kapoor
  • Michael Kolinsky
  • Aly-Khan A. Lalani
  • Jean-Baptiste Lattouf
  • Christopher Morash
  • Scott C. Morgan
  • Tamim Niazi
  • Krista L. Noonan
  • Michael Ong
  • Ricardo A. Rendon
  • Sandeep Sehdev
  • Huong Hew
  • Laura Park-Wyllie Janssen Inc
  • Kim N. Chi`

DOI:

https://doi.org/10.5489/cuaj.6082

Keywords:

Advanced Prostate Cancer, Consensus Statement, Treatment, Management

Abstract

Introduction: The management of advanced prostate cancer (PCa) continues to evolve with the emergence of new diagnostic and therapeutic strategies. As a result, there are multiple areas in this landscape with a lack of high-level evidence to guide practice. Consensus initiatives are an approach to establishing practice guidance in areas where evidence is unclear. We conducted a Canadian-based consensus forum to address key controversial areas in the management of advanced PCa.

Methods: As part of a modified Delphi process, a core scientific group of PCa physicians (n=8) identified controversial areas for discussion and developed an initial set of questions, which were then reviewed and finalized with a larger group of 29 multidisciplinary PCa specialists. The main areas of focus were non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC), metastatic castration-resistant prostate cancer (mCRPC), oligometastatic prostate cancer, genetic testing in prostate cancer, and imaging in advanced prostate cancer. The predetermined threshold for consensus was set at 74% (agreement from 20 of 27 participating physicians).

Results: Consensus participants included uro-oncologists (n=13), medical oncologists (n=10), and radiation oncologists (n=4). Of the 64 questions, consensus was reached in 30 questions (n=5 unanimously). Consensus was more common for questions related to biochemical recurrence, sequencing of therapies, and mCRPC.

Conclusions: A Canadian consensus forum in PCa identified areas of agreement in nearly 50% of questions discussed. Areas of variability may represent opportunities for further research, education, and sharing of best practices. These findings reinforce the value of multidisciplinary consensus initiatives to optimize patient care.

Downloads

Download data is not yet available.

Downloads

Published

2019-11-05

How to Cite

Saad, F., Canil, C., Finelli, A., Hotte, S. J., Malone, S., Shayegan, B., So, A. I., Aaron, L., Basappa, N. S., Conter, H. J., Danielson, B., Gotto, G., Hamilton, R. J., Izard, J. P., Kapoor, A., Kolinsky, M., Lalani, A.-K. A., Lattouf, J.-B., Morash, C., Morgan, S. C., Niazi, T., Noonan, K. L., Ong, M., Rendon, R. A., Sehdev, S., Hew, H., Park-Wyllie, L., & Chi`, K. N. (2019). Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum. Canadian Urological Association Journal, 14(4), E137–49. https://doi.org/10.5489/cuaj.6082

Issue

Vol. 14 No. 4 (2020): CUAJ April

Section

Review

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.